Drug Repurposing Against SARS-CoV-2

Exploration of Repurposed and Adjuvant Drugs in COVID-19 Patients, as well as Challenges and Ethical Issues Related to Drug Repurposing

Author(s): Malti Dadheech and Anand Kumar Maurya * .

Pp: 25-51 (27)

DOI: 10.2174/9789815123197123010005

* (Excluding Mailing and Handling)

Abstract

The Coronavirus Disease (COVID-19), also referred to as Novel Coronavirus Disease, is a contagious viral disease with a high rate of confirmed cases. Therefore, treatment options are urgently needed to fight the deadly virus. Since there is no standard treatment available, it results in increased morbidity and mortality. The development process of a new drug takes years, so it is crucial to focus on repurposed drugs to reduce the severity of this disease. This review aims to describe the regulatory and molecular aspects of repurposed and adjuvant drugs for COVID-19 based on registered clinical trials and online literature. The use of repurposed drugs brings its own ethical issues and challenges. The challenges of the correct interpretation of existing pre-clinical/clinical evidence and the generation of new evidence concerning drug repurposing in COVID-19 and the issues faced by the repurposing community will also be discussed in the review. When drug repurposing is employed in emergency situations, regional limitations of clinical research ethics, involuntary risk burden, regulatory aspects and ethical issues, fairness in resource distribution for repurposed drugs become an issue that requires careful ethical consideration. 


Keywords: Adjuvant drugs, COVID-19, Ethical issues, Repurposed drugs.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy